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Exosomal MicroRNA for Detection of
Cardiac Sarcoidosis
To the Editor:
Sarcoidosis is a multisystem, granulomatous disease of unknown
cause that most commonly affects adults 25–50 years of age, causing
significant morbidity and mortality. Studies indicate that
sarcoidosis-related mortality is on the rise, perhaps relating to
improved disease detection (1). Cardiac sarcoidosis (CS) is the
second leading cause of sarcoidosis-related death, and young
adults are particularly at risk (2). A contributing factor is failure
to detect CS during routine clinical screening, including patient
history, physical examination, and electrocardiography (1).
As a result, many cases are detected for the first time after a
cardiovascular complication, ranging from frequent premature
ventricular contractions and atrial arrhythmias to sudden
cardiac death (1). Whereas high-resolution cardiac imaging
techniques, such as cardiac magnetic resonance or
fludeoxyglucose F 18–positron emission tomography/computed
tomography ([18F]FDG-PET/CT), greatly improve CS detection
(1), these modalities are expensive and present certain patient
risks (e.g., radiation exposure with [18F]FDG-PET/CT [3]),
making them impractical for routine screening for CS. To
our knowledge, no circulating biomarker has been shown to
reliably detect CS.
Noncoding RNAs are readily detected in human blood
and are reported to serve as biomarkers of diseases including
acute myocardial damage (4). A fraction of the microRNAs
(miRNAs) in blood are encapsulated within lipid bilayer vesicles,
referred to as exosomes, where they are shielded from
enzymatic degradation (5). Exosomes originate from multivesicle
bodies within cells containing proteins, nucleic acids, and lipids,
and as such, exosomal molecular content reflects its cellular
origin (6). Thus, we hypothesized that exosome-derived miRNA
could serve as an informative source of biomarkers for cardiac
sarcoidosis.
With institutional review board approval, we conducted a
retrospective study of 21 subjects with histologically proven
sarcoidosis who had clinical and radiographic evidence of CS,
based on established criteria (7, 8), compared with 21 subjects with
sarcoidosis with no evidence of CS (non-CS), and 11 healthy
human volunteers. We randomly divided the plasma samples
obtained into two groups: discovery (10 CS, 10 non-CS, and
5 control) and validation (11 CS, 11 non-CS, and 6 control)
cohorts. The demographic and clinical characteristics are presented
in Table 1, with no significant differences found between the
groups in any of the demographic characteristics. The plasma
samples were collected within the scope of the National Institutes









(N/C/F) MRI* PET† Heart Block‡ V-tachx HFjj
First cohort (NGS analysis)
Control (n = 5) 50.06 3.4 4/1/0 2/3 3/0/2
Cardiac sarcoidosis (n = 10) 51.86 3.1 9/0/1 5/5 8/0/2 50% 30% 60% 50% 40%
Noncardiac sarcoidosis (n = 10) 52.96 3.8 8/1/1 2/8 5/0/5
Second cohort (qRT-PCR analysis)
Control (n = 6) 44.06 5.2 5/1/0 3/3 3/0/3
Cardiac sarcoidosis (n = 11) 54.16 4.1 4/7/0 4/7 10/0/1 27% 55% 64% 27% 36%
Noncardiac sarcoidosis (n = 11) 51.26 3.7 8/3/0 5/6 8/0/3
Definition of abbreviations: HF = heart failure; M/F =male/female; MRI =magnetic resonance imaging; N/C/F = never/current/former; NGS =
next-generation sequencing; PET = positron emission tomography; qRT-PCR = real-time quantitative reverse transcription–polymerase chain reaction;
V-tach = ventricular tachycardia; W/B/O =white/black/other.
*Late gadolinium enhancement on cardiac MRI.
†Patchy left ventricular and/or septal uptake by PET with fludeoxyglucose F 18.
‡Second- or third-degree heart block or bifascicular block.
xNonsustained or sustained spontaneous or inducible V-tach.
jjEvidence of systolic (left ventricular ejection fraction, 50%) or diastolic left ventricular dysfunction by echocardiogram or MRI.
Supported by the Ohio State University Wexner Medical Center Department
of Internal Medicine Pilot grant (E.D.C.) and National Institutes of Health
grant 1 U01 HL112695-01 (N.Y.H. and L.A.M.).




of Health–funded GRADS (Genomic Research in Alpha-1
Antitrypsin Deficiency and Sarcoidosis) research study and were
obtained after patient diagnosis and from those who would
benefit from subsequent treatment (i.e., active cardiac sarcoidosis
as opposed to a more chronic form not requiring intervention).
Exosomes were isolated from the plasma, using a total exosome
isolation kit (Life Technologies, Carlsbad, CA), and total RNA
was extracted (total exosome RNA and protein isolation kit;
Life Technologies). RNA integrity and concentration were
measured with an Agilent 2100 bioanalyzer (Agilent Technologies,
Santa Clara, CA) and a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Wilmington, DE). To identify potential
miRNA biomarkers, we assessed the miRNA spectrum in the
discovery samples by next-generation sequencing (NGS).
Small-RNA sequencing libraries were constructed with an



















































































































































Figure 1. Real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR) validation of selected differentially expressed (DE) transcripts
in plasma exosomal fractions from patients with cardiac sarcoidosis (CS) and patients with sarcoidosis with no evidence of CS (NCS). Of the 13 DE
microRNAs identified by next-generation sequencing (NGS) analysis between CS and NCS plasma exosomal fractions, a select subgroup of the most DE
transcripts was validated by qRT-PCR. (A) Mean1 SE qRT-PCR cycle threshold (Ct) values for miR-16 (to be used for normalization as in NGS) for all the
CS and NCS plasma exosomal samples in the validation cohort. As anticipated, the values were relatively consistent across all samples. The mean Ct
value for miR-16 as determined in the control samples was 30.36 0.9. (B) Relative qRT-PCR expression of select transcripts (miR-7-1-3p, miR-32-3p,
miR-211-5p, and miR-548u-3p) normalized to miR-16 between the CS and NCS plasma exosomal fractions. Three of these four transcripts identified by
NGS were also significantly DE by qRT-PCR analysis (*P, 0.02, Mann-Whitney [rank sum] U test). In the box-and-whisker plots, the middle line
represents the median; the top and bottom of the box represent the third and first quartiles, respectively; and the upper and lower whiskers represent the
highest and lowest data points within 1.53 the interquartile range from the top and bottom of the box, respectively. miR =microRNA.
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Ipswich, MA) and then run on NextSeq 500 high-output kits
(Illumina, San Diego, CA) with single-end 50-nucleotide read
length. Data processing and mapping were performed as described
previously (9), with subsequent miRNA expression internally
normalized to miR-16 levels because of its low concentration
variation among samples used in the study (three independent
real-time quantitative reverse transcription–polymerase chain
reaction [qRT-PCR] results from validation samples are shown in
Figure 1A). Statistical comparisons of differentially expressed
miRNAs (identified when comparing the CS and non-CS
groups) were corrected for multiple hypothesis testing, based
on the Benjamini-Hochberg procedure to reduce false
discovery (10).
The concentrations of 13 miRNAs were specifically different in
exosomes, and not in plasma or exosome-depleted plasma, using a
twofold concentration change threshold when comparing CS
with non-CS (P, 0.05). These miRNAs were as follows:
miR-7-1-3p, miR-32-3p, miR-211-5p, miR-409-5p, miR-517a-3p,
miR-548u-3p, miR-660-3p, miR-942-3p, miR-1262-5p, miR-3179-1-3p,
miR-3940-3p, miR-6855-5p, and miR-7854-5p. Among these, we
selected several of the most affected miRNAs (miR-7-1-3p,
miR-32-3p, miR-211-5p, and miR-548u-3p) for evaluation by
qRT-PCR (normalized to miR-16) in the validation cohort.
Notably, miR-7-1-3p and miR-211-5p are reported biomarkers
of ischemic heart disease (11–13). The concentrations of these
miRNAs were significantly different in all patients with sarcoidosis,
taken collectively, relative to control subjects. Two (miR-32-3p
and miR-211-5p) were found to have higher concentrations in
the non-CS group compared with the CS group, and miR-7-1-3p
was shown by qRT-PCR to be significantly elevated in patients
with CS (Figure 1B). The concentration of miR-548u-3p was not
significantly different between the CS and non-CS groups within
the validation cohort.
Exosomal contents offer a rich source of potential
biomarkers and may reflect the underlying molecular mechanisms
of disease (5). miR-7-1-3p and miR-211-5p have been shown to
be markers of, and in the case of miR-7-1-3p, incriminated in
the pathogenesis of ischemic cardiac disease (11–13). However,
the role of miR-7 in the pathogenesis of CS, if any, remains to
be determined.
Despite the small sample size, statistically significant
concentration differences for specific exosomal miRNAs were
apparent. Given the known limitations of NGS technologies (14),
it was recommended to validate the results using techniques such
as qRT-PCR. Limited by the small quantities of RNA obtained
from exosomes, we were able to validate only a few selected
miRNAs. Although the exosome isolation kit has been claimed
to be highly selective (15), there is a significant amount of
protein copurified with exosomes. It is possible that some of
the miRNA/protein complexes were coprecipitated in the
exosomal fraction. Nevertheless, our NGS data showed that the
concentration changes for each of the 13 differentially expressed
miRNAs were observed only in the exosomal fraction of the
plasma and not in the exosome-depleted plasma samples. Even
though ultracentrifugation offers a more pure exosomal isolation,
it is low throughput, time-consuming, and prohibitory for use in
most clinical applications with limited sample size. Given the
risks and low sensitivity of myocardial biopsy, the diagnosis of
CS is typically established on the basis of clinical criteria. In
this regard, advanced imaging modalities, including magnetic
resonance imaging and [18F]FDG-PET/CT scan, are considered
to be highly sensitive for the detection of CS (1) and can
differentiate active inflammation from more chronic disease
manifestations (e.g., fibrosis) (16). We suspect that the
performance of an exosomal miRNA–based CS biomarker
would be even better if we restricted the analysis to
samples from those having evidence of active myocardial
inflammation.
Our study suggests that specific exosomal miRNAs
could serve as biomarkers of myocardial involvement in
patients with sarcoidosis. Further investigation is needed to
determine whether exosomal miRNA can reflect changes in
cardiac activity (e.g., in response to immune suppression) or
whether miRNA markers from exosomes can detect and
differentiate other sarcoidosis phenotypes (e.g.,
neurosarcoidosis). n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
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The Timing of Early Antibiotics and Hospital Mortality in
Sepsis: Playing Devil’s Advocate
To the Editor:
In this issue of the Journal, Liu and colleagues have reported that
hourly delays in antibiotic administration were associated with
increased odds of hospital mortality even among patients receiving
antibiotics within 6 hours (1) [pp. 856–863]. The overarching
theme and implication of these findings is that clinicians should
strive to deliver antibiotics to patients presenting to the emergency
department (ED) with presumed sepsis as expeditiously as possible
to improve survival (1). We applaud the authors’ intentions of
providing additional evidence that prompt administration of
appropriate antimicrobial therapy in sepsis is lifesaving, but
making this conclusion without following the outcomes of those
patients without sepsis who received prompt, but unnecessary,
antimicrobial therapy, leads to potentially skewed and biased
assumptions (1–5). In fact, the authors make mention of this in
their introduction when they list the potential harms of timely
antibiotic administration (i.e., receipt of antibiotics unnecessarily
culminating in adverse patient and community consequences,
decreased attention to other diseases and patient-specific needs),
but overlook this important fact when discussing their results and
conclusions (1). The intent of this letter is to highlight the
ramifications that neglecting to include those nonseptic patients
who needlessly received antibiotics conceivably had on the
researchers’ results, while urging the investigators to reevaluate
their findings in light of this potential bias.
The authors discuss their approach, which led to the 35,000
patients with sepsis who were included in their retrospective analysis,
which included incorporating patients admitted with sepsis-specific
International Classification of Diseases codes who received antibiotics
within 6 hours of ED registration time (1). However, the authors
neglect to include, and fail to mention, the exclusion of those
patients who received prompt antibiotics who were later found not
to be septic (i.e., presumably those with systemic inflammatory
response syndrome resulting from noninfectious causes or viral
infections) (1). It is these patients who received antibiotics
unnecessarily, and their direct and indirect downstream health
consequences of receiving unneeded antibiotics, that have
significant potential to bias the authors’ conclusion that prompt
antibiotic administration improves survival in patients with
sepsis. A more accurate conclusion given the study’s methodology
might be: for those patients presenting to the ED who received
antibiotics within 6 hours and were admitted with a sepsis-
specific diagnosis, rapid administration of antibiotics was
associated with less odds of mortality.
It is safe to assume that a significant fraction of those nonseptic
patients who received antibiotics unnecessarily had poorer
outcomes and possibly higher mortality than if they never received
antibiotics in the first place (6, 7). To list the potential ways
inappropriate and unnecessary antibiotic administration can cause
harm is beyond the scope of this letter, but suffice it to say there are
many (6, 7).
Overall, we commend the authors for aspiring to demonstrate
that antibiotics administered as quickly as possible in patients
presenting to the ED with a systemic inflammatory response
may improve sepsis survival, but making this conclusion without
incorporating the potential harms of delivering unneeded antibiotics
to nonseptic patients can lead to potentially inaccurate
interpretations. Thus, despite these most recent findings, it
remains imperative that clinicians weigh the benefits of prompt
antibiotic administration with antibiotic stewardship. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
Originally Published in Press as DOI: 10.1164/rccm.201703-0657LE on May
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